Karen Valentine Sells 8,550 Shares of Constellation Pharmaceuticals Inc (NASDAQ:CNST) Stock

Constellation Pharmaceuticals Inc (NASDAQ:CNST) insider Karen Valentine sold 8,550 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $35.03, for a total transaction of $299,506.50. Following the transaction, the insider now owns 14,096 shares of the company’s stock, valued at approximately $493,782.88. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Karen Valentine also recently made the following trade(s):

  • On Thursday, February 13th, Karen Valentine sold 4,473 shares of Constellation Pharmaceuticals stock. The shares were sold at an average price of $35.07, for a total transaction of $156,868.11.

Shares of CNST opened at $36.06 on Friday. Constellation Pharmaceuticals Inc has a one year low of $6.01 and a one year high of $59.49. The company has a 50-day moving average of $38.67 and a two-hundred day moving average of $24.33. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -11.48 and a beta of 6.93. The company has a debt-to-equity ratio of 0.81, a current ratio of 5.19 and a quick ratio of 5.19.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Rhumbline Advisers boosted its holdings in shares of Constellation Pharmaceuticals by 2.4% in the fourth quarter. Rhumbline Advisers now owns 20,331 shares of the company’s stock worth $958,000 after buying an additional 471 shares during the period. Bank of Montreal Can boosted its holdings in shares of Constellation Pharmaceuticals by 43.0% in the fourth quarter. Bank of Montreal Can now owns 1,937 shares of the company’s stock worth $91,000 after buying an additional 582 shares during the period. Victory Capital Management Inc. boosted its holdings in shares of Constellation Pharmaceuticals by 43.4% in the fourth quarter. Victory Capital Management Inc. now owns 2,199 shares of the company’s stock worth $73,000 after buying an additional 666 shares during the period. Meeder Asset Management Inc. acquired a new position in shares of Constellation Pharmaceuticals in the fourth quarter worth about $36,000. Finally, UBS Group AG boosted its holdings in shares of Constellation Pharmaceuticals by 15.9% in the fourth quarter. UBS Group AG now owns 13,905 shares of the company’s stock worth $655,000 after buying an additional 1,912 shares during the period. Institutional investors own 49.91% of the company’s stock.

Several equities analysts have recently weighed in on the stock. BMO Capital Markets lowered shares of Constellation Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $43.00 to $42.00 in a research report on Thursday, January 9th. Oppenheimer raised their price objective on shares of Constellation Pharmaceuticals from $40.00 to $55.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Jefferies Financial Group restated a “buy” rating and set a $40.00 price objective (up previously from $17.00) on shares of Constellation Pharmaceuticals in a research report on Thursday, November 7th. Royal Bank of Canada raised their price objective on shares of Constellation Pharmaceuticals to $42.00 and gave the company a “positive” rating in a research report on Thursday, November 7th. Finally, SunTrust Banks assumed coverage on shares of Constellation Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $50.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $44.09.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.

Featured Article: What is the Consumer Price Index (CPI)?

Insider Buying and Selling by Quarter for Constellation Pharmaceuticals (NASDAQ:CNST)

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.